主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NGNE
#2511
Neurogene, Inc. Common Stock
23.490
0
+21.87%
版块:
基础:
利润货币:
日范围
年范围
日变化
+21.87%
每月变动
+18.04%
6个月变化
-20.16%
年变化
-20.16%
前一天收盘价
19.275
0
Open
23.490
0
Bid
Ask
Low
23.490
0
High
23.490
0
交易量
39
市场
股票
医疗保健
NGNE
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
8.47 M
8.5 M
8.56 M
12.85 M
14.93 M
—
Valuation ratios
Enterprise value
—
—
—
107.18 M
204.7 M
652.93 M
Price to earnings ratio
—
—
—
-0.14
-5.34
-15.71
Price to sales ratio
—
—
—
—
434.14
—
Price to cash flow ratio
—
—
—
0.15
5.69
17.16
Price to book ratio
—
—
—
0.04
1.29
2.12
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.16
0.37
0.5
0.16
0.22
0.28
Return on equity %
0.17
0.42
0.61
0.2
0.24
0.3
Return on invested capital %
2 641.78
1 426.14
1 258.74
2 485.3
1 635.68
—
Gross margin %
100
100
100
—
100
—
Operating margin %
421.02
6.07 M
3 476.29
—
8 930.27
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
415.39
6.07 M
3 385.71
—
8 123.68
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.66
16.67
8.96
8.72
20.84
78.33
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.04
0
0.01
—
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
4.32
4.13
130.28
4.02
3.83
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
12.94
8.73
499.72
17.78
57.3
Net current asset value per share
—
13.08
8.98
507.81
17.98
58.13
Tangible book value per share
—
12.97
8.54
471.5
17.67
57.09
Working capital per share
—
12.3
7.97
449.58
17.12
55.17
Book value per share
—
12.98
8.54
471.5
17.67
57.09
新闻
Netflix, Dell among market cap stock movers on Friday
Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE)
Neurogene股价因FDA突破性疗法认定飙升30%
Neurogene stock surges 30% on FDA breakthrough therapy status
FDA授予Neurogene瑞特综合征疗法突破性疗法认定
FDA grants breakthrough therapy status to Neurogene’s Rett drug
Stifel 重申 Neurogene 股票买入评级,认为其具有可行安全边际
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Neurogene在雷特综合征基因疗法试验中为多名患者给药
Neurogene doses multiple patients in Rett syndrome gene therapy trial
Citizens维持Taysha Gene Therapies股票的市场跑赢评级
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock